Premium
Secondary acute myeloid leukemia after etoposide therapy for haemophagocytic lymphohistiocytosis
Author(s) -
RamaChandran Shanti,
Ariffin Hany
Publication year - 2009
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22063
Subject(s) - etoposide , medicine , myeloid leukemia , hemophagocytic lymphohistiocytosis , oncology , topoisomerase , immunology , disease , chemotherapy , pharmacology , cancer research , dna , biology , genetics
Haemophagocytic lymphohistiocytosis (HLH) is an uncommon disease with a high fatality rate. Etoposide is an important component of current HLH treatment regimes. Two patients with HLH developed etoposide‐related secondary acute myeloid leukemia (sAML) following therapy for HLH. Etoposide, an epipodophyllotoxin, is a topoisomerase II inhibitor that interacts with DNA to potentiate leukaemogenesis. The risk of developing sAML is estimated to be between 1% and 5%, 2–20 years after exposure to etoposide but may also be related to cumulative drug doses, treatment schedules, host factors and co‐administration of other antineoplastic agents. Pediatr Blood Cancer 2009;53:488–490. © 2009 Wiley‐Liss, Inc.